EWTX
Edgewise Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$38.90Close
$4.1BMarket cap
$17.09 – $48.3552-week range
Nov 5, 2026Next report
Highlights
Strengths
- Leading the market RS 91 · stronger than 91% of stocks over 12 months
- Tight base near its pivot pullbacks 27% → 7%; 4.6% below its $40.78 pivot
Cautions
- Trend not confirmed 7 of 8 conditions · under the 50-day
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
20%
1wk
down 1.0%
price change
1mo
down 4.2%
price change
12-month return
up 108%
market up 11% ·
its own up 127%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
7.9×
price / book
Earnings yield
down 4.7%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
0%
return on equity
Free cash margin
—
-$144.1M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
4.9%
$1.89 a day · 2×ATR $35.12
RS
91 / 99
vs the universe
Trend
7 / 8
under the 50-day
Relative volume
0.7×
vs 50-day average
Up/down volume
0.77
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Contractions
2
27% → 7%
Pivot
$40.78
4.6% below
Volume dry-up
0.9×
10 vs 50 sessions
Trend template · 7 of 8
- Price above the 50-day average: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 12.0% over the year, from 95m to 106m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026-4% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$17.2M | -$43.2M | -$71.7M | -$114.4M | -$158.8M | -$191.4M |
| Net income | -$17.1M | -$42.8M | -$67.6M | -$100,163 | -$133,813 | -$167,795 |
| Earnings per share | -$23.17 | -$1.14 | -$1.26 | -$0.00 | -$0.00 | -$0.00 |
| Free cash flow | -$14.8M | -$34.2M | -$58.2M | -$97.7M | -$110.3M | -$144.1M |
| Cash | $104.9M | $15.6M | $22.0M | $86.1M | $41.7M | $61.1M |
| Shareholders' equity | -$33.4M | $274.4M | $346.7M | $318.8M | $459.2M | $522.3M |
| Shares outstanding | 1.01m | 49.50m | 63.26m | 70.45m | 94.84m | 106.25m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Mar 3, 2025 | Annual ↗ | Dec 31, 2024 | 62d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 22, 2024 | Annual ↗ | Dec 31, 2023 | 53d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Results ↗ |
| Jul 13, 2026 | Acquisition or disposal · Regulation FD ↗ |
| Jun 5, 2026 | Shareholder vote ↗ |
| Jun 1, 2026 | Material agreement ↗ |
| May 7, 2026 | Results ↗ |
| Feb 26, 2026 | Results ↗ |
| Nov 20, 2025 | Director or officer change ↗ |
| Nov 10, 2025 | Director or officer change · Regulation FD ↗ |
| Nov 6, 2025 | Results ↗ |
| Aug 7, 2025 | Results ↗ |
| Jun 26, 2025 | Regulation FD · Other events ↗ |
| May 8, 2025 | Results ↗ |